Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT01434394

Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (EAGLE)

Sponsor: Fudan University

Conditions Effects of Chemotherapy Locally Advanced Malignant Neoplasm Oral Cancer Oropharyngeal Carcinoma

Interventions Neo-adjuvant Erbitux-based chemotherapy

Updated 7 times since 2017 Last updated: Aug 16, 2017 Started: Aug 31, 2011 Primary completion: Oct 31, 2014 Completion: Feb 28, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Effects of Chemotherapy and Locally Advanced Malignant Neoplasm, this trial is completed. The trial is conducted by Fudan University and has accumulated 7 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Sep 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

Status: Unknown Status → Completed

▶ Show 2 earlier versions

Feb 2017 — Sep 2017 [monthly]

Unknown Status PHASE2_PHASE3

Status: Recruiting → Unknown Status
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE2_PHASE3

First recorded

Aug 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fudan University
Second Military Medical University
Shanghai Jiao Tong University School of Medicine
Tongji University

Data source: Shanghai Jiao Tong University School of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China